Remaining Gaps and Unmet Needs in ROS1-Positive NSCLC

Martin Dietrich, MD, PhD, names testing as the first gap that remains, followed by a limited understanding of how resistance develops and when to retest. Dietrich is interested in combination approaches, whether with chemotherapy or a second targeted agent, and in moving these well-tolerated agents into earlier, curative-intent settings, while noting most patients present with symptomatic or metastatic disease. Wade Iams, MD, reframes the numbers from the patient's side, saying a median progression-free survival of four years sounds impressive to oncologists but lands very differently on someone diagnosed in their mid-40s or mid-50s. Ticiana Leal, MD, adds co-mutations, frontline combinations, and unresectable stage III disease, where immunotherapy is likely ineffective, and notes an adjuvant trial is ongoing.